Virus Fight: Gilead, Moderna, Two On The Front Lines, To Report Q2 Results

Ahead of earnings from two of the most closely watched biotechs--Moderna (MRNA) and Gilead (GILD)--one thing seems pretty certain: Few investors are likely to care much less than normal about Q2 financial numbers from either.